慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究*

doi:10.3969/j.issn.1672-5069.2022.02.010

Abstract

Abstract: Objective The aim of this study was to explore the relationship between liver X receptor α (LXRα) and cytochrome P450 isoform 7A1 (CYP7A1) expression and liver histopathological inflammatory grading and fibrotic staging in patients with chronic hepatitis B (CHB). Methods 118 patients with CHB were enrolled in our hospital between January 2019 and October 2020, all patients underwent liver biopsies and histological activity >=G2 and liver fibrosis >=S2 were defined as significant inflammation or significant fibrosis. The expression and their mRNA levels of LXRα and CYP7A1 in liver tissues were detected by immunohistochemical staining and by RT-PCR. Results The positive rates of hepatic LXRα和CYP7A1mRNA and/or their proteins in 118 patients with CHB were 78.0% and 73.7%, respectively; the LXRα mRNA level and its protein expression in 38 patients with significant liver inflammation were (0.6±0.2) and (0.3±0.1)average optical density (AOD), significantly higher or stronger than [(0.4±0.1) and (0.1±0.0)AOD, respectively, P<0.05] in 80 patients without significant hepatic histopathological inflammation, and the CYP7A1 mRNA level and its protein expression were (0.8±0.2) and (0.4±0.1)AOD, significantly higher or stronger than [(0.3±0.1) and (0.1±0.0)AOD, respectively, P<0.05] in patients without significant hepatic inflammation; the LXRα mRNA and its protein expression in 48 patients with significant liver fibrosis were (0.7±0.2) and (0.3±0.1)AOD, significantly higher or stronger than [(0.3±0.1) and (0.1±0.1)AOD, P<0.05] in 70 patients without significant liver fibrosis, and the CYP7A1 mRNA level and its protein expression were (0.7±0.2)and (0.3±0.1)AOD, significantly higher or stronger than [(0.4±0.2) and (0.2±0.1)AOD, respectively, P<0.05] in patients without significant liver fibrosis. Conclusion The up-regulation of LXRα and CYP7A1 gene might be involved in the pathogenesis of liver inflammation and fibrosis, which needs further investigation.

Key words: Hepatitis B, Liver X receptor α, Cytochrome P450 isoform 7A1, Liver histology

Li Zhen, Ning Shanshan, Guo Ying, et al. Hepatic expression of liver X receptorα and cytochrome P450 isoform 7A1 in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(2): 191-194.

References

[1] Mesnage R, Renney G, Séralini GE, et al. Author correction: multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of roundup herbicide. Sci Rep,2018,8(1):12572-12578.
[2] Wong YJ, Kalki RC, Lin KW, et al. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. Singapore Med J,2020,61(8):419-425.
[3] 邓羊羊,葛善飞,余燕青,等. 肝细胞核因子1α在慢性乙型肝炎患者肝脏炎症及纤维化发生发展过程中的表达变化及其意义. 中华肝脏病杂志,2021,29(2):121-125.
[4] Chen PC, Chen BH, Huang CH, et al. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol,2019,31(10):1256-1263.
[5] Suliman I, Abdelgelil N, Kassamail F, et al. The effect of hepatic steatotis on the natural history of HBV infection. Clin Liver Dis,2019,23(3):443-450.
[6] Zeng J, Wu D, Hu H, et al. Activation of the liver x receptor pathway inhibits HBV replication in primary human hepatocytes. Hepatology,2020,72(6):1935-1948.
[7] Mak JSM, Lao TT, Leung MBW, et al. Ovarian HBV replication following ovulation induction in female hepatitis B carriers undergoing ivf treatment: a prospective observational study. J Viral Hepat,2020,27(2):110-117.
[8] 吴文楠,曾勇彬,林锦骠,等. 福建省汉族乙型肝炎病毒感染者胆固醇7α-羟化酶基因的多态性分析. 中华检验医学杂志,2018,41(2):155-164.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[10] 周志凌,印倩. 慢性乙型肝炎病毒携带者血清GP73水平与肝组织病理学变化的关系研究. 实用肝脏病杂志,2018,21(5):717-720.
[11] Grinman DY, Careaga VP, Wellberg EA, et al. Liver x receptor-α activation enhances cholesterol secretion in lactating mammary epithelium. Am J Physiol Endocrinol Metab,2019,316(6):1136-1145.
[12] Wu HM, Kim TH, Kim A, et al. Liverx receptor α-induced cannabinoid receptor 2 inhibits ubiquitin-specific peptidase 4 through mir-27b, protecting hepatocytes from TGF-β. Hepatol Commun,2019,3(10):1373-1387.
[13] Eid SA, El Massry M, Hichor M, et al. Targeting the nadph oxidase-4 and liver x receptor pathway preserves schwann cell integrity in diabetic mice. Diabetes,2020,69(3):448-464.
[14] Zinkhan EK, Yu B, McKnight R. Uteroplacental insufficiency impairs cholesterol elimination in adult female growth-restricted rat offspring fed a high-fat diet. Reprod Sci,2019,26(9):1173-1180.
[15] Zuo H, Su X, Jin Y, et al. Transthyretin regulated by linc00657/mir-205-5p promoted cholesterol metabolism by inducing srebp2-hmgcr and inhibiting lxrα-cyp7a1. Arch Med Res,2020,51(4):317-326.
[16] Zhou Y, Chen Z, Lin Q, et al. Nuciferine reduced fat deposition by controlling triglyceride and cholesterol concentration in broiler chickens. Poult Sci,2020,99(12):7101-7108.
[17] Srivastava RAK, Cefalu AB, Srivastava NS, et al. Npc1l1 and abcg5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with ppar-α and lxr agonists. Mol Cell Biochem,2020,473(1):247-262.
[18] 王俐钧,孙建光. 基于LXRα/FAS通路探讨茵杞调脂饮治疗大鼠非酒精性脂肪肝病的作用机制. 中华中医药杂志,2019,34(10):4566-4570.
[19] Song XY, Wu WF, Gabbi C, et al. Retinal and optic nerve degeneration in liver x receptorβ knockout mice. Proc Natl Acad Sci USA,2019,116(33):16507-16512.

Hepatic expression of liver X receptorα and cytochrome P450 isoform 7A1 in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yang Yan, Liu Ting, Dai Lin, et al. Noninvasive assessment of liver fibrosis via liver and spleen stiffness measurement using acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(2): 183-186.
[2]	Huang Ping, Zeng Xia, Zhang Yaping, et al. Evaluation of significant liver fibrosis by hepatic vein waveform classification and ultrasound-based semi-quantitative scoring in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(2): 187-190.
[3]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[4]	Yan Jingquan, Wang Chunling, Liu Juan, et al. Predictive value of antiviral response by serum hepatitis B virus pregenomic RNA levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2022, 25(1): 22-25.
[5]	Qu Xiaowei, Feng Lili, Mao Yanyun. Clinical implication of peripheral blood T lymphocyte subset changes in patients with syphilis and hepatitis B or hepatitis C coinfection [J]. Journal of Practical Hepatology, 2022, 25(1): 34-37.
[6]	Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control. Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of Practical Hepatology, 2021, 24(6): 776-785.
[7]	Xu Zhengheng, Huang Yong, Ke Haixia, et al. Correlation of peripheral blood mononuclear cell galectin-3 levels in patients with chronic hepatitis B receiving interferon-α therapy [J]. Journal of Practical Hepatology, 2021, 24(6): 811-814.
[8]	Xue Kui, Xu Yinhai, Zhang Jian. Changes of serum thrombopoietin levels and its relationship with peripheral blood platelet counts in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 891-894.
[9]	Wang Ligong, Zhao Shan, Bai Kai, et al. Serum α1 acidic glycoprotein, α1-antitrypsin and haptoglobin levels could be applied to predict hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(5): 673-676.
[10]	Wu Fengping, Lu Rui, Liu Yixin, et al. Serum HBsAg clearance in sequential combination of peginterferon alpha-treated patients with chronic hepatitis B with low serum HBsAg levels after nucleos(t)ide analogs treatment [J]. Journal of Practical Hepatology, 2021, 24(5): 677-680.
[11]	Zhou Bingqing, Yang Hanqing, Jiang Beili. Re-treatment of chronic hepatitis B non-responders to pegylated interferon-α by tenofovir and entecavir [J]. Journal of Practical Hepatology, 2021, 24(5): 681-684.
[12]	Yang Yonghan, Lu Ping, Meng Qingning, et al. Quantitative evaluation of hepatic fibrosis in patients with chronic hepatitis B by enhanced MRI T1 mapping [J]. Journal of Practical Hepatology, 2021, 24(5): 685-688.
[13]	Chen Dandan, Long Zhida, Huang Shundong, et al. Risk factors of infection and acute kidney injury in patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2021, 24(5): 717-720.
[14]	Yang Yanqiu, Cheng Hao, Feng Min. Evaluation of significant liver fibrosis in patients with chronic hepatitis B by ultrasonic elastography and serological indexes [J]. Journal of Practical Hepatology, 2021, 24(4): 480-483.
[15]	Wu Hui, Song Bo, Lyu Chengxiu, et al. Change of serum endoplasmic reticulum stress parameters in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(4): 484-487.